Ruifudi provides health science solutions, cutting-edge technology, and professional services, covering the end-to-end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of deep cultivation in fields such as multi omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Ruifudi is breaking through the boundaries of human potential with the power of technology. In 2023, Ruifudi's revenue exceeded 2.7 billion US dollars, with over 11000 employees worldwide, providing diversified services to clients such as pharmaceutical and biotechnology companies, diagnostic laboratories, research institutions, and government agencies. The company is a member of the S&P 500 index and has clients in over 190 countries and regions worldwide.
